top of page

Suman Paul Lab @

Clinical Reports

Our clinical reports describe the outcomes of patients with various blood cancers that receive novel antibodies and cell therapies.

Read our clinical reports

Improved Overall Survival with Checkpoint Inhibition and Allogeneic Transplantation in Relapsed Hodgkin Lymphoma

Blood Advances, 2024

Allogeneic Blood or Marrow Transplantation with High-Dose Post-transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Aged≥ 55

Transplantation and Cellular Therapy, 2022

Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source

Transplantation and Cellular Therapy, 2022

Checkpoint blockade treatment sensitises relapsed/refractory non‐Hodgkin lymphoma to subsequent therapy

British Journal of Haematology, 2020

Checkpoint blockade treatment may sensitize Hodgkin lymphoma to subsequent therapy

The Oncologist, 2020

Non-myeloablative allogeneic transplantation with post-transplant cyclophosphamide after immune checkpoint inhibition for classic Hodgkin lymphoma: a retrospective cohort study

Biology of Blood and Marrow Transplantation, 2020

Impact of treatment beyond progression with immune checkpoint blockade in Hodgkin lymphoma

The Oncologist, 2020

Allogeneic haploidentical blood or marrow transplantation with post-transplantation cyclophosphamide in chronic lymphocytic leukemia

Biology of Blood and Marrow Transplantation, 2020

bottom of page